One hundred million US dollars, intraxon and ziopharm add another fire to car-t research!

Source: Biovalley 2015-01-15 January 15, 2015 with the improvement of medical technology, scientists are increasingly aware that the human immune system may be the most powerful weapon against diseases As a result, immunotherapy has become increasingly popular in the field of medical research and development since last year Many biomedical giants have invested huge human and material resources in this field It can be said that in 2015, if a pharmaceutical company doesn't do some research on tumor immunotherapy, you are embarrassed to say hello to your peers In many immunotherapies, car-t therapy is the most promising Recently, two pharmaceutical companies, intraxon and ziopharm, jointly invested $100 million to add another fire to the field The company announced a $100 million partnership with the Anderson Cancer Research Center at the University of Texas to develop the corresponding car-t therapy Different from the traditional methods of Juno and Novartis, Anderson Cancer Research Center has established a non viral vector system to immunize T cells This avoids many potential risks According to the agreement, Anderson Cancer Research Center will provide two companies with five candidate drugs to complete the preclinical research this year Car-t therapy is to isolate patients' T cells, use chimeric antigen to immunize them in vitro, make these T cells become a "missile" to kill specific tumor cells, then expand the culture and return to patients Because these cells are derived from patients themselves, the risk of individual differences and side effects will be greatly reduced At present, Novartis is the leading company in this field Juno and kite followed On the other hand, Johnson & Johnson and Pfizer have also invested heavily in the hope of a spectacular counter attack Let's wait and see who can be the last winner in this competition